I think hims can pull it off, people in the glp 1 industry will be able to understand the quality difference of them vs bottom of the barrel amazon
@chaoticsalsa10 күн бұрын
Agree
@Mike-ym6rl10 күн бұрын
Amazon's relentless pursuit of competitor's margins could spell disaster for healthcare. Hims & Hers, on the other hand, offers a compelling investment opportunity with a focus on quality and customer satisfaction.
@chaoticsalsa10 күн бұрын
I had to pause after 2 min and 53 seconds. You, seriously, need to do your research before you give people financial advice. You are clearly not aware that HIMS is selling GLP1s and the dates on that graph that are dips are related entirely to news articles that were released. There is another big date today as the FDA decides if the shortages for GLP1s can continue. I'm not going to go much farther into the nuance, because you failed to capture the basics. How could you make a recommendation about a stock without knowing about the GLP1 business. Wasn't Zack's about data -- Zack's Rank? Is this the quality of the research we should expect from Zack's in the future? You do this for a living?